PDF(Pubmed)
Abstract：
Mesenchymal stem/stromal cells (MSCs) are one of the most widely used cell types in advanced therapies due to their therapeutic potential in the regulation of tissue repair and homeostasis, and immune modulation. However, their use in cancer therapy is controversial: they can inhibit cancer cell proliferation, but also potentially promote tumour growth by supporting angiogenesis, modulation of the immune milieu and increasing cancer stem cell invasiveness. This opposite behaviour highlights the need for careful and nuanced use of MSCs in cancer treatment. To optimize their anti-cancer effects, diverse strategies have bioengineered MSCs to enhance their tumour targeting and therapeutic properties or to deliver anti-cancer drugs. In this review, we highlight the advanced uses of MSCs in cancer therapy, particularly as carriers of targeted treatments due to their natural tumour-homing capabilities. We also discuss the potential of MSC-derived extracellular vesicles to improve the efficiency of drug or molecule delivery to cancer cells. Ongoing clinical trials are evaluating the therapeutic potential of these cells and setting the stage for future advances in MSC-based cancer treatment. It is critical to identify the broad and potent applications of bioengineered MSCs in solid tumour targeting and anti-cancer agent delivery to position them as effective therapeutics in the evolving field of cancer therapy.
摘要：
间充质干细胞/基质细胞（MSCs）是先进疗法中最广泛使用的细胞类型之一，因为它们在调节组织修复和稳态方面具有治疗潜力。和免疫调节。然而,它们在癌症治疗中的使用是有争议的:它们可以抑制癌细胞增殖，但也可能通过支持血管生成来促进肿瘤生长，调节免疫环境和增加癌症干细胞侵袭力。这种相反的行为突出了在癌症治疗中仔细和细致入微地使用MSC的需要。为了优化它们的抗癌效果，不同的策略有生物工程MSCs以增强其肿瘤靶向和治疗特性或提供抗癌药物。在这次审查中,我们强调了MSCs在癌症治疗中的高级用途，特别是作为靶向治疗的载体，由于其天然的肿瘤归巢能力。我们还讨论了MSC衍生的细胞外囊泡提高药物或分子递送至癌细胞的效率的潜力。正在进行的临床试验正在评估这些细胞的治疗潜力，并为基于MSC的癌症治疗的未来进展奠定了基础。至关重要的是，确定生物工程MSC在实体瘤靶向和抗癌剂递送中的广泛而有效的应用，以将其定位为不断发展的癌症治疗领域中的有效治疗剂。
